Maruti Suzuki India has confirmed a price hike across its entire vehicle lineup, effective February 1, 2025. This decision comes as the company faces rising input costs and operational expenses. In a regulatory filing, Maruti Suzuki stated that while efforts are being made to manage costs, some of the burden will inevitably be passed on to customers.

Maruti Suzuki India Ltd shares are currently trading at ₹12,024.90, down by ₹20.85 (0.17%) as of 11:01 AM on January 24, showing a 20.37% gain over the past year but a 3.72% decline in the last six months.

Hike Details

The price increase will vary across models, ranging from ₹1,500 to ₹32,500. The largest hike of ₹32,500 will apply to the Celerio, while premium models like the Invicto and Jimny will see increases of ₹30,000 and ₹1,500, respectively. Other models such as the Wagon-R, Swift, and Dzire will experience hikes of ₹13,000, ₹5,000, and ₹10,500, respectively.

Model-Wise Price Changes

Sales Figures for December 2024

In December 2024, Maruti Suzuki sold 1,78,248 units, a 30% increase compared to the previous year. This included 1,32,523 domestic sales, 37,419 exports, and 8,306 units sold to other OEMs.

Company Statement

The company talked about its commitment to minimising customer impact but acknowledged that external cost pressures necessitate a price hike. Maruti Suzuki’s vehicles currently range from ₹3.99 lakh for the Alto K10 to ₹28.92 lakh for the Invicto.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Vishnu Prakash R Punglia Limited (VPRPL), along with its joint venture partners RBIPL and the Jaipur Development Authority (JDA), has been awarded a contract for constructing a 30 MLD (megalitres per day) sewerage treatment plant at Swarn Vihar, Sanganer, Jaipur.

The project will use Sequential Batch Reactor (SBR) technology, an approach to wastewater treatment. The Office of the Executive Engineer of JDA issued the Letter of Acceptance on January 23, 2025. The total value of the contract stands at ₹513.99 Million.

Details of the Project

The scope of the project includes engineering, procurement, construction, commissioning, and operational performance testing, followed by operations and maintenance (O&M). This tender was evaluated and finalized after a competitive bidding process, with VPRPL-RBIPL-JDA-JV emerging as the selected contractor.

Other Projects Secured by VPRPL

This is the third major order secured by VPRPL in January 2025. On January 2, the company was chosen as the lowest bidder for a ₹43.31 crore road development project in Rajasthan. This project involves the construction of a 2 lane bypass with paved shoulders and a new rail overbridge (ROB) to Mandal town in Bhilwara district.

On January 1, VPRPL secured another contract valued at ₹31.34 crore for elevation works of academic blocks at the Fintech Digital Institute in Jodhpur. The project was given by the Department of Information Technology and Communication, Government of Rajasthan.

Background

VPRPL, founded in 1986, is a construction and infrastructure firm with a presence in nine states and one union territory in India. The company is into building projects such as highways, flyovers, bridges, and residential complexes. As of September 30, 2023, the company reported an order book worth ₹5,086 crore.

Market Performance

Following the announcement of the Jaipur contract,  As of 10:53 AM today, on January 24, Vishnu Prakash R Punglia Ltd’s shares were trading at ₹250.70, down by 1.36% today, but showing a 12.29% rise over the past six months and up a 17.73% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Economic Explosives Limited (EEL), a subsidiary of Solar Industries India Limited, has entered into an agreement with the Government of Maharashtra to develop a major defence and aerospace project in Nagpur. The MoU was signed on January 22, 2025, at the World Economic Forum in Davos, Switzerland. The proposed project will require an investment of approximately ₹12,700 crore.

As of 11:17 AM today, on January 24, Solar Industries India Ltd is priced at ₹9,578.85, marking a modest intraday rise of ₹19.95 (0.21%). While the stock has dipped by 9.32% over the past six months, it has delivered a 44.61% gain over the past year.

Focus on Defence Manufacturing

The project is to expand production capacity in areas including drones, unmanned aerial vehicles (UAVs), counter-drone systems, explosives, and other materials. Additionally, the initiative will include the development of new products, such as military transport aircraft.

The state government has agreed to assist EEL with the necessary approvals, permissions, registrations, and fiscal incentives required for the project. These facilitation measures will align with Maharashtra’s existing policies and regulations.

Other Developments 

Solar Industries has been expanding in the defence sector since its entry in 2010. The company recently secured export orders worth ₹2,039 crore for defence products. These orders, to be delivered over 4 years, shows the company’s presence in global markets.

Financial Overview

Solar Industries India Limited has a market capitalisation of over ₹86,000 crore. The company has a compound annual growth rate (CAGR) of 28.1% in profits over the past five years. As of September 2024, its order book stands at ₹5,757 crore.

Defence Sector

The Nagpur project represents a huge investment in the country’s defence and aerospace. By focusing on manufacturing and product diversification, EEL’s plans align with the broader goal of boosting the country’s strategic infrastructure. The project is to drive both technological and industrial growth in the region.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

RPP Infra Projects Limited, a prominent name in India’s infrastructure sector, has been awarded a significant contract worth ₹28.77 crore (inclusive of GST). The project involves the erection, testing, and commissioning of an Air Cooled Condenser (ACC) and its associated auxiliaries for Unit 2 at the 3×800 MW PVUNL STPP in Patratu, Jharkhand.

This contract highlights the company’s technical capabilities and commitment to executing complex infrastructure projects within the stipulated timeframes.

RPP Infra’s share price was trading down by 1.22% as of 2:18 PM on January 23, 2025.

Scope of the Project

The scope of work involves comprehensive activities, including:

Material Handling and Transportation:

• Receipt of materials from the store and transportation to the project site.

Erection and Commissioning Activities:

• Erection, testing, commissioning, and trial runs of the Air Cooled Condenser system.
• Final handing over of the system.

Key Structural and Mechanical Installations:

• Installation of structures, finned tube bundles, steam distribution manifolds, axial fan systems, and wind wall structures.
• Auxiliary systems such as elevators, air removal systems, condensate systems, steam ducting, and draining systems.

Finishing Touches and Auxiliary Work:

• Cleaning, lifting devices, insulation, finish painting, and installation of required structures.
• Platforms, stairs, hoists, chain pulley blocks, EOT cranes, and temporary passenger elevators.

The completion of this project will strengthen the infrastructure at the Patratu facility, further enhancing its operational efficiency

Key Project Highlights

1. Awarding Authority: Bharat Heavy Electricals Limited (BHEL)
2. Project Value: ₹28.77 crore (including GST)
3. Timeline: The project is expected to be completed within 10 months.
4. Execution Location: Patratu, Jharkhand

RPP Infra’s role in such critical projects underscores its reliability and expertise in delivering high-stakes infrastructure solutions.

Strategic Significance

This project aligns with India’s growing focus on renewable and thermal power infrastructure. RPP Infra Projects’ association with BHEL for this contract demonstrates its ability to cater to the evolving needs of the sector. The timely completion of such initiatives not only strengthens the company’s project portfolio but also contributes to the national goal of sustainable development.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

January 23, 2025, Emcure Pharmaceuticals, a leading name in the Indian pharmaceutical sector, marked a significant milestone by inaugurating its state-of-the-art Formulation Research and Development (R&D) Centre near Tapovan Circle, Ahmedabad, Gujarat. This facility, aptly named the Emcure Research Centre (ERC), underscores the company’s commitment to advancing healthcare through cutting-edge drug delivery systems and innovative formulations.

Emcure Pharmaceuticals’ share price was trading marginally down by 0.17% on the NSE as of 2:05 PM on January 23, 2025.

A World-Class Facility for Transformative Research

The ERC is equipped with advanced laboratories and technology to enable breakthroughs in complex drug delivery systems, including sustained-release formulations, liposomal injections, and dermal therapies. By seamlessly integrating all aspects of pharmaceutical development—from pre-formulation to scale-up—the facility adheres to stringent global regulatory standards, setting a benchmark for excellence in pharmaceutical research.

Empowering Talent and Enhancing Patient Care

A dedicated team of 350 skilled professionals, comprising doctorate holders, postgraduates, and graduates from various fields like pharmaceutical sciences, bio-engineering, and regulatory affairs, will drive research initiatives at ERC. Their focus is on creating patient-centric solutions, improving drug bioavailability, and developing innovative formulations that address unmet medical needs.

Promoting Sustainability and Collaboration

Reflecting Emcure’s dedication to environmentally conscious practices, the ERC prioritises green chemistry and sustainable solutions. Moreover, the centre aims to foster collaborations with academic institutions, industry experts, and regulatory bodies, thereby creating an ecosystem of shared knowledge and innovation. This initiative not only boosts pharmaceutical advancements but also generates employment opportunities, strengthening Gujarat’s position as a hub for pharmaceutical research.

A Message from Gujarat’s Health Minister

Shri Rushikeshbhai Patel, Honourable Minister of Health and Family Welfare, Government of Gujarat said, “It gives me great pride to inaugurate Emcure Pharmaceuticals’ advanced R&D centre in Ahmedabad. Gujarat has always been a hub for innovation and progress, and this facility is a shining example of how we can create futuristic healthcare solutions. By investing in drug research and nurturing local talent, Emcure is not only contributing to Gujarat’s growth but also strengthening India’s position as a global leader in pharmaceuticals. I compliment the entire team at Emcure for this remarkable achievement”.

Emcure’s Vision for the Future

“Over the past four decades, Emcure has remained steadfast in its commitment to pushing the boundaries of pharmaceutical research and development, creating innovative solutions for unmet medical challenges”, said Mr. Satish Mehta, Founder and CEO, of Emcure Pharmaceuticals. “This new R&D centre represents a significant milestone in our continued pursuit of innovation, by combining advanced research technology with a talented team. With a focus on both efficiency and quality, the centre is set to drive advancements that will reshape the future of medicine globally”, he concluded.

About Emcure Pharmaceuticals

Established in 1981 and headquartered in Pune, Emcure Pharmaceuticals ranks as the 12th largest pharma company in India by domestic sales (MAT June 2024). Operating in over 70 countries, including Europe and Canada, the company is renowned for its innovation, quality, and patient-centric approach across a broad range of therapeutic areas.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.